Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M89,528Revenue $M26,095Net Margin (%)3.8Z-Score2.5
Enterprise Value $M93,310EPS $1.0Operating Margin %7.1F-Score4
P/E(ttm))92.8Cash Flow Per Share $0Pre-tax Margin (%)4.1Higher ROA y-yN
Price/Book4.510-y EBITDA Growth Rate %11.7Quick Ratio0.8Cash flow > EarningsY
Price/Sales3.55-y EBITDA Growth Rate %-5.8Current Ratio1.0Lower Leverage y-yY
Price/Cash Flow0y-y EBITDA Growth Rate %-29.4ROA % (ttm)1.8Higher Current Ratio y-yN
Dividend Yield %4.1Insider Buy (3m)0ROE % (ttm)4.5Less Shares Outstanding y-yN
Payout Ratio %343Shares Outstanding M1,263ROI % (ttm)0Gross Margin Increase y-yN

Gurus Latest Trades with AZN

Number of guru portfolios checked: 85. (List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)
TickerGuruDate Action
Impactdown Price Range
(Average)*
Current Price Change from Average Comment Current Shares
AZNDavid Dreman 2014-12-31 Reduce-0.51%$67.15 - $75.38
($71.66)
$ 68.9-4%Reduce -75.42%28,764
AZNGeorge Soros 2014-12-31 Sold Out -0.08%$67.15 - $75.38
($71.66)
$ 68.9-4%Sold Out0
AZNMario Gabelli 2014-12-31 Reduce-0.01%$67.15 - $75.38
($71.62)
$ 68.9-4%Reduce -52.51%19,900
AZNCharles Brandes 2014-09-30 Sold Out -0.35%$68.49 - $76.31
($73.2)
$ 68.9-6%Sold Out0
AZNJohn Hussman 2014-09-30 Reduce-0.29%$68.49 - $76.31
($73.2)
$ 68.9-6%Reduce -22.37%173,500
AZNGeorge Soros 2014-06-30 Buy 0.08%$62.45 - $81.09
($72.26)
$ 68.9-5%New holding, 150000 sh.150,000
AZNMario Gabelli 2014-06-30 Buy 0.02%$62.45 - $81.09
($72.26)
$ 68.9-5%New holding, 40400 sh.40,400
AZNCharles Brandes 2014-06-30 Reduce-0.78%$62.45 - $81.09
($72.26)
$ 68.9-5%Reduce -71.06%386,058
AZNJoel Greenblatt 2014-06-30 Sold Out -0.09%$62.45 - $81.09
($72.26)
$ 68.9-5%Sold Out0
AZNNWQ Managers 2014-06-30 Reduce-0.01%$62.45 - $81.09
($72.26)
$ 68.9-5%Reduce -24.55%64,475
AZNJohn Hussman 2014-03-31 Add0.96%$58.51 - $68.15
($64.29)
$ 68.97%Add 714.29%228,000
AZNDavid Dreman 2014-03-31 Add0.14%$58.51 - $68.38
($64.41)
$ 68.97%Add 26.61%135,439
AZNJoel Greenblatt 2014-03-31 Buy 0.09%$58.51 - $68.38
($64.41)
$ 68.97%New holding, 95518 sh.95,518
AZNHOTCHKIS & WILEY 2014-03-31 Sold Out -0.93%$58.51 - $68.38
($64.41)
$ 68.97%Sold Out0
AZNCharles Brandes 2014-03-31 Reduce-0.84%$58.51 - $68.15
($64.29)
$ 68.97%Reduce -46.73%1,333,894
AZNDavid Dreman 2013-12-31 Reduce-0.34%$49.72 - $59.5
($54.28)
$ 68.927%Reduce -40.32%106,975
AZNHOTCHKIS & WILEY 2013-12-31 Reduce-0.3%$49.72 - $59.5
($54.28)
$ 68.927%Reduce -24.9%3,689,214
AZNJohn Hussman 2013-12-31 Reduce-0.11%$49.72 - $59.5
($54.28)
$ 68.927%Reduce -58.82%28,000
AZNCharles Brandes 2013-09-30 Add0.12%$47.88 - $52.08
($50.24)
$ 68.937%Add 7.92%2,381,040
AZNJohn Hussman 2013-09-30 Reduce-0.66%$47.88 - $52.08
($50.24)
$ 68.937%Reduce -81.87%68,000
Premium Real Time Picks are included for Premium Members only!!
*The price and date might not be the actual time and price at which the transactions were made. In the case of institutional owners, the date is stated as the last day of their fiscal quarter. The prices are estimates if no accurate information available. Foreign holdings may not be included.

AZN is held by these Gurus:

Ticker Guru Name Portfolio Date* Current Shares % of Shares Outstanding % of Total Assets Managed Change from Last Holdings Holding History
AZN NWQ Managers 2014-12-3166,4400.010.06+3.05%
AZN John Hussman 2014-12-31173,5000.011.2
AZN Mario Gabelli 2014-12-3119,90000.01-52.51%
AZN David Dreman 2014-12-3128,76400.17-75.42%
AZN George Soros 2014-12-31000Sold Out
Premium Most recent portfolio changes are included for Premium Members only!


AZN: Insider Buys/Sells

Click Here for All Insider Trades.
InsiderPosition Date Trades Shares Trade Price ($) Change (%) Details
ASTRAZENECA PLC10% Owner 2014-11-12Sell2,000,000$17305.29view

Press Releases about AZN :

    Quarterly/Annual Reports about AZN:

      News about AZN:

      Articles On GuruFocus.com
      Pfizer Stocks Has A Lot Of Steam To Take The Investors Higher Jan 20 2015 
      Merck Takes A Step Forward In The World Of Medicine Jan 16 2015 
      Brandes International Equity Fund Q3 Commentary Dec 23 2014 
      Blackhill Bets Almost Half of Portfolio on Williams-Sonoma Nov 10 2014 
      A Look at the Top Five Medical Stocks Held in the Vanguard Portfolio Nov 09 2014 
      Steven Cohen Has a Track Record of Impressive Returns Jul 31 2014 
      I Believe AstraZeneca Is Fairly Valued Jul 16 2014 
      A Look at AstraZeneca’s New Drug on Diabetes May 22 2014 
      Gulf Resources (GURE) Impressive Performance, Amgen (AMGN) and AstraZeneca (AZN) Positive Data From May 11 2014 
      Can Pfizer Make Up Its Loss? May 09 2014 


      More From Other Websites
      Horizon Pharma Soars On Q4 Beat, Guidance Raise Feb 27 2015
      AstraZeneca to carve out antibiotic R&D into separate firm Feb 27 2015
      AstraZeneca carving out antibiotic R&D into separate firm Feb 27 2015
      (OFFICIAL)-UPDATE 1-Actavis' superbug antibiotic gets U.S. approval (Feb. 25) Feb 26 2015
      (OFFICIAL)-UPDATE 1-Actavis' superbug antibiotic gets U.S. approval (Feb. 25) Feb 26 2015
      Rigel Pharma CEO pulls back the curtain on drug deal with Bristol-Myers Feb 26 2015
      US District Court decision in PULMICORT RESPULES® (budesonide inhalation suspension) patent... Feb 26 2015
      Can Isis Pharmaceuticals (ISIS) Beat Earnings this Season? - Analyst Blog Feb 25 2015
      Nektar Therapeutics Incurs Narrower-than-Expected Q4 Loss - Analyst Blog Feb 25 2015
      Alkermes Falls on Pipeline News; Q4 Earnings Plunge Y/Y - Analyst Blog Feb 25 2015
      AstraZeneca taps biotech firm Orca for autoimmune disease drugs Feb 25 2015
      Agilent-ONO Companion Diagnostics Aim - Analyst Blog Feb 23 2015
      Patents mean big business to big pharma Feb 23 2015
      Salix Pharmaceuticals: Will Another Buyer Push Valeant's Bid Higher? Feb 23 2015
      Fast facts Feb 23 2015
      Should You Buy AstraZeneca plc Instead Of Hikma Pharmaceuticals Plc, BTG plc And GW Pharmaceuticals... Feb 23 2015
      AstraZeneca PLC fourth quarter and full year results 2014 Feb 22 2015
      MedImmune, NIST announce five-year partnership for biological drug research Feb 20 2015
      Jefferies Names AbbVie As Top Pharmaceutical Pick, Offers Alternative Choices Feb 20 2015
      A 'Great Entry Point' for AbbVie; Pfizer a 'Value Creation Machine' Feb 20 2015

      Add Notes, Comments

      If you want to ask a question, or report a bug, please create a support ticket.

      User Comments

      No comment yet
      Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
      GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
      Free 7-day Trial
      FEEDBACK